Benjamin P. Levy, MD

Articles

Dr. Levy on the Efficacy of Crizotinib Versus Entrectinib in ROS1+ Lung Cancer

July 24th 2020

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

Dr. Levy on Emerging Biomarkers and Corresponding Therapies in Lung Cancer

April 4th 2020

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.

Dr. Levy on the Current State of Liquid Biopsies Across Tumor Types

February 22nd 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Dr. Levy on Repeat Testing in NSCLC

February 20th 2020

Benjamin P. Levy, MD, discusses the importance of repeat testing in non–small cell lung cancer.

Dr. Levy on Ongoing Research Evaluating the Use of Liquid Biopsies in Lung Cancer

February 8th 2020

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer

January 24th 2020

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Dr. Levy on Treatments for Oncogenic-Driven NSCLC

December 21st 2019

Benjamin P. Levy, MD, discusses treatment options for patients with oncogenic-driven non–small cell lung cancer.

Dr. Levy on First-Line Treatment for Nondriver NSCLC

November 28th 2019

Benjamin P. Levy, MD, discusses first-line treatment for patients with nondriver non–small cell lung cancer.

Dr. Levy on Molecular Drivers in NSCLC

November 15th 2019

Benjamin P. Levy, MD, discusses the identification of molecular drivers in non–small cell lung cancer.

Dr. Levy Discusses the Outlook for Oncogene-Driven NSCLC

May 30th 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the outlook for patients with oncogene-driven non–small cell lung cancer.

Dr. Levy on the Benefits of Liquid Biopsies in NSCLC

May 22nd 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the benefits of liquid biopsies in non–small cell lung cancer.

Dr. Levy on Entrectinib in Oncogene-Driven NSCLC

March 29th 2019

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of Medical Oncology, Sidney Kimmel Cancer Center and Johns Hopkins Medicine, discusses the use of entrectinib in patients with NTRK-mutant and ROS1-rearranged non–small cell lung cancer.

Dr. Levy on Investigational Biomarkers of Response to Immunotherapy in NSCLC

September 7th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses investigational biomarkers of response to immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Levy on Biomarkers of Response to Immunotherapy

August 24th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses biomarkers of response to immunotherapy.

Dr. Levy on Therapy for Rapidly Progressing NSCLC

August 2nd 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses therapy options for patients with rapidly progressing non–small cell lung cancer (NSCLC).

Dr. Levy on the Application of Liquid Biopsies in NSCLC

July 4th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the application of liquid biopsies in non–small-cell lung cancer (NSCLC).

Dr. Levy Discusses the FLAURA Study in Lung Cancer

February 22nd 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the FLAURA study in patients with lung cancer.

Dr. Levy Discusses Pembrolizumab in NSCLC

February 13th 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in non-small cell lung cancer.

Dr. Levy on the Treatment of T790M-Mutant Lung Cancer

December 29th 2017

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the treatment options for patients with T790M-mutant lung cancer.

Dr. Levy on Impact of Nivolumab, Pembrolizumab Approvals in NSCLC

April 12th 2016

Benjamin P. Levy, MD, assistant professor of Medicine, Hematology, and Medical Oncology at Mount Sinai Hospital, discusses how nivolumab (Opdivo) and pembrolizumab (Keytruda) have impacted the treatment landscape of non–small cell lung cancer.

NEXT PAGE
PREVIOUS PAGE